Integra LifeSciences Holdings (Nasdaq: IART) reported earnings on Oct. 24. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased significantly.

Gross margins dropped, operating margins contracted, net margins grew.

Revenue details
 Integra LifeSciences Holdings recorded revenue of $210.1 million. The 14 analysts polled by S&P Capital IQ expected sales of $211.4 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter's $202.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.85. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.77 per share. GAAP EPS of $0.46 for Q3 were 18% higher than the prior-year quarter's $0.39 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 62.1%, 70 basis points worse than the prior-year quarter. Operating margin was 9.4%, 480 basis points worse than the prior-year quarter. Net margin was 6.3%, 70 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $216.9 million. On the bottom line, the average EPS estimate is $0.83.

Next year's average estimate for revenue is $834.5 million. The average EPS estimate is $3.04.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 157 members out of 169 rating the stock outperform, and 12 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.27.